The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
Table 6
Predictive factors of PVTT in hepatocellular carcinomas.
Parameters
Univariate analysis
Multivariate analysis
OR (95% CI)
OR (95% CI)
Age (≤ 50 vs. > 50)
0.443 (0.253-0.774)
0.040
0.414 (0.214-0.799)
0.009
Sex (male vs. female)
1.036 (0.449-2.388)
0.934
TBIL
1.032 (1.006-1.058)
0.016
1.025 (0.995-1.056)
0.100
Tumor size
3.845 (1.370-10.789)
0.011
2.515 (0.258-24.55)
0.428
Tumor differentiation (well vs. moderately/poorly)
1.025 (0.280-3.753)
0.971
Tumor multiplicity (single vs. multiple)
3.065 (1.745-5.381)
< 0.001
2.118 (1.097-4.089)
0.025
BCLC staging
6.053 (1.522-24.071)
0.011
0.211 (0.012-3.824)
0.292
AFP
2.641 (1.312-5.318)
0.007
1.536 (0.710-3.323)
0.276
PIVKA-II
7.346 (2.579-20.921)
< 0.001
4.890 (1.361-38.169)
0.020
TBIL: total bilirubin; AFP: alpha-fetoprotein; PIVKA-II: protein induced by vitamin K absence or antagonist-II; CI: confidence interval; PVTT: portal vein tumor thrombus; Significant difference ().
